Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.61 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069970 | 1.00 | PPARA (0.61) | PPARACHEK2CNR1CNR2PRMT5 | |
| SCHEMBL2069079 | 0.86 | PPARA (0.48) | PPARACHEK2CNR1CNR2NR1D1 | |
| SCHEMBL2069058 | 0.83 | MEN1 (0.48) | CHEK2CNR1CNR2PRMT5WDR77 | |
| SCHEMBL2069460 | 0.83 | CNR1 (0.52) | PPARACNR1CNR2PPARD | |
| SCHEMBL2070708 | 0.82 | PPARA (0.48) | PPARACNR1CNR2HRH3RAB9A | |
| SCHEMBL2069575 | 0.79 | MEN1 (0.48) | PPARAMEN1KMT2APPARDRAB9A | |
| SCHEMBL2069085 | 0.79 | PPARA (0.42) | PPARANR1D1MEN1KMT2AFFAR1 | |
| SCHEMBL2069528 | 0.77 | PPARA (0.63) | PPARACNR1CNR2PPARD | |
| SCHEMBL2069366 | 0.77 | PPARA (0.63) | PPARACNR1CNR2PPARD | |
| SCHEMBL2069584 | 0.77 | PPARA (0.59) | PPARACNR1CNR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902367-B2 | Cyclic amino benzoic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902367-B2 | Cyclic amino benzoic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902367-B2 | Cyclic amino benzoic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20090036489-A1 | Novel Cyclic Aminophenylalkanoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20090036489-A1 | Novel Cyclic Aminophenylalkanoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20090036489-A1 | Novel Cyclic Aminophenylalkanoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1862464-A1 | NOVEL CYCLIC AMINOPHENYLALKANOIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2007-12-05 | — | — | EP | disclosed |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1780210-A1 | NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2007-05-02 | — | — | EP | disclosed |
| EP-1780210-A1 | NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2007-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036489-A1 | Novel Cyclic Aminophenylalkanoic Acid Derivative | PPARA, PPARD, PPARG | PPARA 1/4885CHEK2 3869/4885CNR1 159/4885 |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | PPARA, PPARG, PPARD | PPARA 1/4885CHEK2 3810/4885CNR1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.